After injection with ultra rapid lispro (URLi), insulin appeared in the blood at approximately 1 min. Compared with Humalog®, insulin appearance was five times faster and early insulin exposure was up to seven-fold greater with URLi, resulting in greater early glucose-lowering effect. Insulin also left the blood sooner, reducing the late glucose-lowering effect of URLi compared with Humalog, and potentially reducing the occurrence of late hypoglycaemia seen with rapid-acting insulins.

The pharmacokinetic and glucodynamic differences between URLi and Humalog observed in younger adult patients were maintained in elderly patients with type 1 diabetes.

The ultra-rapid pharmacokinetic and glucodynamic profile of URLi has the potential to improve postmeal glucose control over current rapid-acting insulin analogs.